Continued studies with Pelvipharm to generate knowledge about treatment times, doses and Libiguin’s® mechanism of action
Press release: Uppsala, October 12, 2020. As previously reported, Dicot has conducted the first study in collaboration with Pelvipharm SAS with tests in a model for erectile function in normal rats. Satisfactory results showed that treatment with Dicot's substance Libiguin® has a dose-dependent effect in these animals. Likewise, Sildenafil (Viagra), the reference compound routinely used in this model, displayed the expected effect on erectile functions of normal rats.In this first study, the experimental animals were dosed in a similar way that was originally used in folk medicine use in